Pacira | PCRX - Zinsaufwendungen Für Schuld





Zinsaufwendungen Für Schuld Veränderung Datum
Astellas Pharma JPY 3.91B 320M 2025-03
Bristol-Myers Squibb USD 407M 4M 2026-06
Cara Therapeutics -89.64M 128.67M 2025-12
Coherus Biosciences USD 2.25M 76K 2025-12
Heron Therapeutics USD 600K 100K 2024-12
Ironwood Pharmaceuticals USD 8.74M 506K 2024-12
J&J USD 43M 25M 2026-03
Ligand Pharmaceuticals USD 1.78M 875K 2025-12
Nektar Therapeutics USD 7.94M 1.83M 2026-03
Novo Nordisk DKK 1.5B 28M 2026-06
Omeros USD 4.05M 5.16M 2024-09
Pacira USD 3.62M 77K 2026-06
Perrigo USD 7.61B 373.8M 2026-06
Pfizer USD 667M 4M 2026-06
Supernus Pharmaceuticals USD 910K 278K 2023-06
Teva Pharmaceutical Industries USD 195M 21M 2026-06
Xeris Pharmaceuticals USD 6.88M 269K 2026-03
Zoetis USD 61M 1000K 2026-06